APTORUM GROUP LIMITED

(APM)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
1.070 USD   -3.60%
05/17Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
BU
05/02Aptorum Says Rare Cancer Drug Well Tolerated in Early-Stage Study
MT
05/02Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aptorum Group 30% Higher Premarket After FDA Orphan Drug Designation

01/20/2022 | 08:56am EDT

By Michael Dabaie


Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted orphan drug designation to SACT-1.

The designation is for the treatment of patients with neuroblastoma. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% to 10% of all childhood tumors, the company said.

Aptorum Group plans to file an investigational new drug application to begin a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

01-20-22 0856ET

All news about APTORUM GROUP LIMITED
05/17Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, M..
BU
05/02Aptorum Says Rare Cancer Drug Well Tolerated in Early-Stage Study
MT
05/02Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targ..
BU
05/02Aptorum Group Limited Updates on Data from Completed Phase 1 Clinical Trial of SACT-1, ..
CI
04/29APTORUM : Reports 2021 Fiscal Year End Financial Results and Provides Business Update - Fo..
PU
04/29Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 202..
CI
04/29Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Busin..
BU
04/29APTORUM GROUP LIMITED : SEC Filing 6K-4
CO
04/29APTORUM GROUP LIMITED : Annual results
CO
04/29APTORUM GROUP LIMITED : SEC Filing 20 F
CO
More news
Financials (USD)
Sales 2022 1,50 M - -
Net income 2022 -35,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,07x
Yield 2022 -
Capitalization 38,2 M 38,2 M -
Capi. / Sales 2022 25,5x
Capi. / Sales 2023 20,1x
Nbr of Employees 26
Free-Float 25,4%
Chart APTORUM GROUP LIMITED
Duration : Period :
Aptorum Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTORUM GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,07 $
Average target price 15,00 $
Spread / Average Target 1 302%
EPS Revisions
Managers and Directors
Ian Huen Director
Darren Lui President & Executive Director
Sabrina Khan Chief Financial Officer
Clark Cheng Executive Director & Chief Medical Officer
Wai-Yip Lee Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
APTORUM GROUP LIMITED-28.67%38
JOHNSON & JOHNSON2.59%470 547
PFIZER, INC.-14.65%288 063
ABBVIE INC.12.58%273 513
ELI LILLY AND COMPANY6.87%271 308
ROCHE HOLDING AG-14.97%263 868